October 31st, 2022 Ubiquigent obtains exclusive license for UbiSite® technology to strengthen its specialist drug discovery services
July 5th, 2022 Ubiquigent appoints Professor Helen Walden and Professor John Davis to Scientific Advisory Board
December 14th, 2021 Ubiquigent celebrates milestone anniversary of DUBprofiler™ compound profiling platform
December 14th, 2021 Ubiquigent celebrates milestone anniversary of DUBprofiler™ compound profiling platform
October 26th, 2021 Ubiquigent Extends and Expands Drug Discovery Collaboration with Bristol Myers Squibb